30 closest matches · ranked by relevance
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Immune Thrombocytopenia
Primary: Percentage of Time With a Platelet Response During the First 6 Months of Treatment — 50.00 percentage of time
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Immune Thrombocytopenia
Primary: Proportion of Patients With a Platelet Response — 52; 14 Participants
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment — 128; 37; 3; 11 Participants
Thrombocytopenia
Primary: Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study — 80.0; 60.0; 58.3; 91.7 percentage of participants
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants
Immune Thrombocytopenic Purpura
Primary: Platelet Response — 80.7 Percent of participants
Immune Thrombocytopenia
Primary: Durable Platelet Response — 15; 0 Participants — p=0.0077
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Immune Thrombocytopenia
Primary: Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall — 44.4; 0.0; 40.0; 40.0 percentage of participants
Purpura, Thrombocytopenic, Idiopathic
Primary: Remission Duration — 3; 11 Participants
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Responders — 2; 1; 7; 37 Percentage of participants — p=<0.001
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Immune (Idiopathic) Thrombocytopenic Purpura
Primary: Responder Patients — 72.2 percentage of subjects
Idiopathic Thrombocytopenic Purpura
Primary: Achievement Rate of Stable Platelet Response — 36.4; 0.0 Percentage of participants — p=0.030
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenic Purpura
Primary: Adverse Events — 162; 215 participants
Immune Thrombocytopenia (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 0; 25 percentage of participants
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 — 13.7; 16.2 percentage of…